-
1
-
-
67349233062
-
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
-
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
-
(2009)
Leukemia
, vol.23
, pp. 1054-1061
-
-
Hochhaus, A.1
O'Brien, S.G.2
Guilhot, F.3
Druker, B.J.4
Branford, S.5
Foroni, L.6
-
2
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
Cortes, J.4
Shah, S.5
Ayala, M.6
-
3
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
Le Coutre, P.4
Etienne, G.5
Lobo, C.6
-
4
-
-
84988566338
-
Treatment and outcome of 2904 CML patients from the EUTOS populationbased registry
-
Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF et al. Treatment and outcome of 2904 CML patients from the EUTOS populationbased registry. Leukemia 2017; 31: 593-601.
-
(2017)
Leukemia
, vol.31
, pp. 593-601
-
-
Hoffmann, V.S.1
Baccarani, M.2
Hasford, J.3
Castagnetti, F.4
Di Raimondo, F.5
Casado, L.F.6
-
5
-
-
0038454621
-
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
-
Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
-
(2003)
Blood
, vol.101
, pp. 4701-4707
-
-
Bhatia, R.1
Holtz, M.2
Niu, N.3
Gray, R.4
Snyder, D.S.5
Sawyers, C.L.6
-
6
-
-
84973137731
-
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
-
Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648-1671.
-
(2016)
Leukemia
, vol.30
, pp. 1648-1671
-
-
Steegmann, J.L.1
Baccarani, M.2
Breccia, M.3
Casado, L.F.4
Garcia-Gutierrez, V.5
Hochhaus, A.6
-
7
-
-
79959311524
-
Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008
-
Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514-2520.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2514-2520
-
-
Bjorkholm, M.1
Ohm, L.2
Eloranta, S.3
Derolf, A.4
Hultcrantz, M.5
Sjoberg, J.6
-
8
-
-
78049528573
-
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (STIM) trial
-
Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
-
(2010)
Lancet Oncol
, vol.11
, pp. 1029-1035
-
-
Mahon, F.X.1
Rea, D.2
Guilhot, J.3
Guilhot, F.4
Huguet, F.5
Nicolini, F.6
-
9
-
-
84886917643
-
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study
-
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522.
-
(2013)
Blood
, vol.122
, pp. 515-522
-
-
Ross, D.M.1
Branford, S.2
Seymour, J.F.3
Schwarer, A.P.4
Arthur, C.5
Yeung, D.T.6
-
10
-
-
85010049735
-
Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia
-
e-pub ahead of print 31 October 2016
-
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 2016; e-pub ahead of print 31 October 2016; doi:10.1200/JCO.2016.68.2914.
-
(2016)
J Clin Oncol
-
-
Etienne, G.1
Guilhot, J.2
Rea, D.3
Rigal-Huguet, F.4
Nicolini, F.5
Charbonnier, A.6
-
11
-
-
84960941451
-
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial
-
Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015; 2: e528-e535.
-
(2015)
Lancet Haematol
, vol.2
, pp. e528-e535
-
-
Imagawa, J.1
Tanaka, H.2
Okada, M.3
Nakamae, H.4
Hino, M.5
Murai, K.6
-
12
-
-
16244366026
-
Index for rating diagnostic tests
-
Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
-
(1950)
Cancer
, vol.3
, pp. 32-35
-
-
Youden, W.J.1
-
13
-
-
77956634317
-
The BCR/ABLinhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
-
Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR et al. The BCR/ABLinhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-2128.
-
(2010)
Int J Cancer
, vol.127
, pp. 2119-2128
-
-
Salih, J.1
Hilpert, J.2
Placke, T.3
Grunebach, F.4
Steinle, A.5
Salih, H.R.6
-
14
-
-
38949210227
-
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
-
Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
-
(2008)
Blood
, vol.111
, pp. 1366-1377
-
-
Schade, A.E.1
Schieven, G.L.2
Townsend, R.3
Jankowska, A.M.4
Susulic, V.5
Zhang, R.6
-
15
-
-
15244351682
-
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner
-
Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner. Blood 2005; 105: 2473-2479.
-
(2005)
Blood
, vol.105
, pp. 2473-2479
-
-
Seggewiss, R.1
Lore, K.2
Greiner, E.3
Magnusson, M.K.4
Price, D.A.5
Douek, D.C.6
-
16
-
-
33846023983
-
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
-
Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
-
(2007)
Blood
, vol.109
, pp. 58-60
-
-
Rousselot, P.1
Huguet, F.2
Rea, D.3
Legros, L.4
Cayuela, J.M.5
Maarek, O.6
-
17
-
-
33646877669
-
Human natural killer cell development and biology
-
Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20: 123-137.
-
(2006)
Blood Rev
, vol.20
, pp. 123-137
-
-
Farag, S.S.1
Caligiuri, M.A.2
-
18
-
-
84957596020
-
CD57 in human natural killer cells and T-lymphocytes
-
Kared H, Martelli S, Ng TP, Pender SL, Larbi A. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother 2016; 65: 441-452.
-
(2016)
Cancer Immunol Immunother
, vol.65
, pp. 441-452
-
-
Kared, H.1
Martelli, S.2
Ng, T.P.3
Pender, S.L.4
Larbi, A.5
-
20
-
-
84924984567
-
Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function
-
Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42: 443-456.
-
(2015)
Immunity
, vol.42
, pp. 443-456
-
-
Schlums, H.1
Cichocki, F.2
Tesi, B.3
Theorell, J.4
Beziat, V.5
Holmes, T.D.6
-
21
-
-
84924955835
-
Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals
-
Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015; 42: 431-442.
-
(2015)
Immunity
, vol.42
, pp. 431-442
-
-
Lee, J.1
Zhang, T.2
Hwang, I.3
Kim, A.4
Nitschke, L.5
Kim, M.6
-
22
-
-
33846467149
-
CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
-
Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21: 356-359.
-
(2007)
Leukemia
, vol.21
, pp. 356-359
-
-
Grzywacz, B.1
Kataria, N.2
Verneris, M.R.3
-
23
-
-
10144247247
-
Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism
-
Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-584.
-
(1996)
J Exp Med
, vol.184
, pp. 579-584
-
-
Zheng, L.M.1
Ojcius, D.M.2
Garaud, F.3
Roth, C.4
Maxwell, E.5
Li, Z.6
-
24
-
-
84896702820
-
Moving towards patient-centered decisionmaking in chronic myeloid leukemia: Assessment of quality of life and symptom burden
-
Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decisionmaking in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 2014; 99: 205-208.
-
(2014)
Haematologica
, vol.99
, pp. 205-208
-
-
Baccarani, M.1
Efficace, F.2
Rosti, G.3
-
25
-
-
84977624843
-
Moving treatment-free remission into mainstream clinical practice in CML
-
Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016; 128: 17-23.
-
(2016)
Blood
, vol.128
, pp. 17-23
-
-
Hughes, T.P.1
Ross, D.M.2
-
26
-
-
84973176467
-
The concept of treatment-free remission in chronic myeloid leukemia
-
Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 2016; 30: 1638-1647.
-
(2016)
Leukemia
, vol.30
, pp. 1638-1647
-
-
Saussele, S.1
Richter, J.2
Hochhaus, A.3
Mahon, F.X.4
-
27
-
-
0022616253
-
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
-
Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
-
(1986)
Nature
, vol.319
, pp. 675-678
-
-
Karre, K.1
Ljunggren, H.G.2
Piontek, G.3
Kiessling, R.4
-
28
-
-
0035855872
-
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
-
Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171.
-
(2001)
Nature
, vol.413
, pp. 165-171
-
-
Diefenbach, A.1
Jensen, E.R.2
Jamieson, A.M.3
Raulet, D.H.4
-
29
-
-
0035949563
-
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
-
Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 11521-11526
-
-
Cerwenka, A.1
Baron, J.L.2
Lanier, L.L.3
-
30
-
-
84857996055
-
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice
-
Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012; 26: 465-474.
-
(2012)
Leukemia
, vol.26
, pp. 465-474
-
-
Chen, C.I.1
Koschmieder, S.2
Kerstiens, L.3
Schemionek, M.4
Altvater, B.5
Pscherer, S.6
-
31
-
-
84900418447
-
Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy
-
Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS ONE 2014; 9: e87794.
-
(2014)
PLoS ONE
, vol.9
, pp. e87794
-
-
Ilander, M.1
Kreutzman, A.2
Rohon, P.3
Melo, T.4
Faber, E.5
Porkka, K.6
-
32
-
-
79961240453
-
Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile
-
Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 2011; 6: e23022.
-
(2011)
PLoS ONE
, vol.6
, pp. e23022
-
-
Kreutzman, A.1
Rohon, P.2
Faber, E.3
Indrak, K.4
Juvonen, V.5
Kairisto, V.6
-
33
-
-
84879703012
-
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
-
Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121: 3599-3608.
-
(2013)
Blood
, vol.121
, pp. 3599-3608
-
-
Romee, R.1
Foley, B.2
Lenvik, T.3
Wang, Y.4
Zhang, B.5
Ankarlo, D.6
-
34
-
-
13444262764
-
Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming
-
Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5: 1260-1265.
-
(2004)
Nat Immunol
, vol.5
, pp. 1260-1265
-
-
Martin-Fontecha, A.1
Thomsen, L.L.2
Brett, S.3
Gerard, C.4
Lipp, M.5
Lanzavecchia, A.6
-
35
-
-
0036143496
-
Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection
-
Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002; 3: 83-90.
-
(2002)
Nat Immunol
, vol.3
, pp. 83-90
-
-
Kelly, J.M.1
Darcy, P.K.2
Markby, J.L.3
Godfrey, D.I.4
Takeda, K.5
Yagita, H.6
-
36
-
-
0036569402
-
A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo
-
Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ. A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002; 168: 4472-4479.
-
(2002)
J Immunol
, vol.168
, pp. 4472-4479
-
-
Kelly, J.M.1
Takeda, K.2
Darcy, P.K.3
Yagita, H.4
Smyth, M.J.5
-
37
-
-
84863338121
-
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
-
Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119: 2665-2674.
-
(2012)
Blood
, vol.119
, pp. 2665-2674
-
-
Foley, B.1
Cooley, S.2
Verneris, M.R.3
Pitt, M.4
Curtsinger, J.5
Luo, X.6
-
38
-
-
59049094662
-
Adaptive immune features of natural killer cells
-
Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457: 557-561.
-
(2009)
Nature
, vol.457
, pp. 557-561
-
-
Sun, J.C.1
Beilke, J.N.2
Lanier, L.L.3
-
39
-
-
79951695881
-
Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection
-
Sun JC, Beilke JN, Bezman NA, Lanier LL. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 2011; 208: 357-368.
-
(2011)
J Exp Med
, vol.208
, pp. 357-368
-
-
Sun, J.C.1
Beilke, J.N.2
Bezman, N.A.3
Lanier, L.L.4
-
40
-
-
80052602721
-
Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
-
Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011; 108: 14725-14732.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 14725-14732
-
-
Lopez-Verges, S.1
Milush, J.M.2
Schwartz, B.S.3
Pando, M.J.4
Jarjoura, J.5
York, V.A.6
-
42
-
-
84869856060
-
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
-
Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317-4323.
-
(2012)
Blood
, vol.120
, pp. 4317-4323
-
-
Vey, N.1
Bourhis, J.H.2
Boissel, N.3
Bordessoule, D.4
Prebet, T.5
Charbonnier, A.6
|